Tag #Pharmaceutical Industry

Showing 73 to 84 of 152 results

theglobeandmail.com

🌐 85% Global Worthiness

May 6, 04:09

Canadian Health Data Companies Sell Patient Records to Pharma Firms Without Consent

A Canadian study reveals that health data companies are selling patient records to pharmaceutical firms without patient knowledge, using two monetization models: a conventional model and a vertically integrated model involving direct clinic ownership. This raises significant ethical and privacy conc...

Canadian Health Data Companies Sell Patient Records to Pharma Firms Without Consent

A Canadian study reveals that health data companies are selling patient records to pharmaceutical firms without patient knowledge, using two monetization models: a conventional model and a vertically integrated model involving direct clinic ownership. This raises significant ethical and privacy conc...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of Canadian health data companies selling patient records to pharmaceutical companies without consent?

A new study reveals that Canadian health data companies are selling patient records to pharmaceutical firms without patient consent, creating "complex reciprocal relationships" between data brokers, physicians, clinics, and pharmaceutical companies. Physicians are sometimes compensated for identifying potential trial participants or customers from patient records, raising significant privacy concerns. This practice generates potentially hundreds of millions of dollars.

theguardian.com

🌐 85% Global Worthiness

May 1, 16:13

Trump Hints at Tariff Reprieve for Pharma

President Trump hinted at delaying pharmaceutical import tariffs, offering companies time to relocate production to the US before facing levies; this follows similar actions in other sectors and comes as the industry braced for 25% tariffs as early as next week.

Trump Hints at Tariff Reprieve for Pharma

President Trump hinted at delaying pharmaceutical import tariffs, offering companies time to relocate production to the US before facing levies; this follows similar actions in other sectors and comes as the industry braced for 25% tariffs as early as next week.

Progress

52% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

What is the immediate impact of Trump's suggestion on pharmaceutical companies anticipating new tariffs?

President Trump hinted at a potential delay for pharmaceutical import tariffs, offering companies "a lot of time" to move operations to the US before facing levies. This follows previous tariff pauses on other sectors, suggesting a pattern of response to business opposition. The potential delay could affect drugmakers expecting 25% tariffs as early as next week.

dailymail.co.uk

🌐 85% Global Worthiness

Apr 30, 04:15

AstraZeneca Shifts Production to US Amidst Europe's Lagging Pharmaceutical Investment

AstraZeneca CEO Pascal Soriot announced a shift of manufacturing to the US due to potential tariffs, highlighting Europe's lagging pharmaceutical investment and emphasizing the US's dominant role in funding pharmaceutical innovation; the company reported a 10% revenue increase for Q1 2025, with onco...

AstraZeneca Shifts Production to US Amidst Europe's Lagging Pharmaceutical Investment

AstraZeneca CEO Pascal Soriot announced a shift of manufacturing to the US due to potential tariffs, highlighting Europe's lagging pharmaceutical investment and emphasizing the US's dominant role in funding pharmaceutical innovation; the company reported a 10% revenue increase for Q1 2025, with onco...

Progress

48% Bias Score

ShareSaveArticle

Industry, Innovation, and Infrastructure

12345678

Previous 1 of 8 Next

How might the planned US tariffs on pharmaceutical imports affect the global pharmaceutical landscape, and what are the potential consequences for both US and European companies?

Pascal Soriot, AstraZeneca's CEO, warned Europe is falling behind in pharmaceutical investment compared to the US. He highlighted that the US's significant investment incentivizes companies to move jobs and research there. AstraZeneca's shift in manufacturing to the US demonstrates the impact of this imbalance, prompting calls for increased European investment to maintain competitiveness.

welt.de

🌐 75% Global Worthiness

Apr 23, 10:10

German Pharma Growth in 2024: Export Boom, Tariff Threat

Germany's pharmaceutical sector projects 2.5% revenue growth and 1,100 new jobs in 2024, driven by increased US exports due to tariff fears; however, potential US tariffs pose risks to supply chains and profitability.

German Pharma Growth in 2024: Export Boom, Tariff Threat

Germany's pharmaceutical sector projects 2.5% revenue growth and 1,100 new jobs in 2024, driven by increased US exports due to tariff fears; however, potential US tariffs pose risks to supply chains and profitability.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of increased US demand on the German pharmaceutical sector and economy?

The German pharmaceutical industry projects a 2.5% revenue increase and 2.9% production growth in 2024, adding 1,100 jobs. This contrasts with the stagnant German economy and is driven by increased exports, a stable domestic market, and preemptive US stockpiling due to threatened tariffs.

theglobeandmail.com

🌐 85% Global Worthiness

Apr 20, 19:14

US Drug Tariff Investigation Threatens Canadian Pharmaceutical Exports

The Trump administration is investigating pharmaceutical imports, potentially impacting \$7 billion in Canadian exports; the Bank of Canada held interest rates steady due to trade war uncertainty; and Canadian restaurants are booming as Canadians avoid U.S. travel.

US Drug Tariff Investigation Threatens Canadian Pharmaceutical Exports

The Trump administration is investigating pharmaceutical imports, potentially impacting \$7 billion in Canadian exports; the Bank of Canada held interest rates steady due to trade war uncertainty; and Canadian restaurants are booming as Canadians avoid U.S. travel.

Progress

44% Bias Score

ShareSaveArticle

No Poverty

12345678

Previous 1 of 8 Next

What are the immediate economic consequences of the U.S. investigation into pharmaceutical imports for Canada?

The Trump administration initiated an investigation into the pharmaceutical supply chain, potentially impacting Canadian pharmaceutical exports worth over \$7 billion. Generic drugmakers like Apotex and Pharmascience could be significantly affected. This action contrasts with the White House and Florida's promotion of Canadian drug importation to reduce costs.

cnn.com

🌐 85% Global Worthiness

Apr 16, 07:14

Trump Executive Order Targets Drug Prices, Medicare Costs

President Trump issued a multi-part executive order on Tuesday aiming to lower drug prices and reduce Medicare costs by modifying Medicare drug price negotiations, standardizing Medicare payments for prescription drugs, and increasing transparency in pharmaceutical pricing; however, some provisions ...

Trump Executive Order Targets Drug Prices, Medicare Costs

President Trump issued a multi-part executive order on Tuesday aiming to lower drug prices and reduce Medicare costs by modifying Medicare drug price negotiations, standardizing Medicare payments for prescription drugs, and increasing transparency in pharmaceutical pricing; however, some provisions ...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key provisions of President Trump's executive order on healthcare costs, and what immediate impacts are expected?

President Trump issued an executive order aiming to lower drug prices and reduce Medicare costs. The order includes provisions to modify Medicare drug price negotiations, standardize Medicare payments for prescription drugs, and increase transparency in pharmaceutical pricing. However, some provisions require Congressional cooperation, and immediate impact is unlikely.

cincodias.elpais.com

🌐 75% Global Worthiness

May 2, 10:12

Novo Nordisk's Telemedicine Deal to Counter Eli Lilly in Obesity Drug Market

Novo Nordisk partnered with Hims & Hers Health to sell its Wegovy weight-loss drug through telemedicine platforms at discounted prices, directly competing with Eli Lilly's Zepbound strategy amid insurance coverage challenges and following a recent stock decline of over 30% since January 2025, after ...

Novo Nordisk's Telemedicine Deal to Counter Eli Lilly in Obesity Drug Market

Novo Nordisk partnered with Hims & Hers Health to sell its Wegovy weight-loss drug through telemedicine platforms at discounted prices, directly competing with Eli Lilly's Zepbound strategy amid insurance coverage challenges and following a recent stock decline of over 30% since January 2025, after ...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What immediate impact will Novo Nordisk's telemedicine partnership have on its revenue and market share in the obesity drug sector?

Novo Nordisk, facing investor uncertainty due to concerns about future treatments, announced a new agreement with Hims & Hers Health to sell Wegovy via telemedicine platforms at reduced prices. This follows Eli Lilly's similar strategy with Zepbound, highlighting the growing use of telemedicine to increase sales amid challenges in securing insurance coverage for obesity drugs. This partnership aims to boost revenue and compete with Eli Lilly.

dailymail.co.uk

🌐 75% Global Worthiness

May 1, 04:13

Europe Faces Pharmaceutical Investment Crisis Amid US Competition

GSK's CEO Emma Walmsley and other pharmaceutical leaders warn that Europe risks losing jobs and investment to the US unless more support is provided to the industry, following GSK's announcement of better-than-expected first-quarter results with sales rising 2 percent to £7.5 billion and profits up ...

Europe Faces Pharmaceutical Investment Crisis Amid US Competition

GSK's CEO Emma Walmsley and other pharmaceutical leaders warn that Europe risks losing jobs and investment to the US unless more support is provided to the industry, following GSK's announcement of better-than-expected first-quarter results with sales rising 2 percent to £7.5 billion and profits up ...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the higher profitability of the US pharmaceutical market contribute to the industry's shift toward investment in the US?

The pharmaceutical industry's competitiveness is threatened by the US's higher drug prices and potential tariffs, prompting calls for increased European investment. This competition is driving pharmaceutical companies to invest more heavily in the US, where profits are greater. GSK, which derives over half its sales from the US, exemplifies this trend.

lemonde.fr

🌐 85% Global Worthiness

Apr 26, 07:14

Keytruda's $30 Billion Success: Revolutionizing Cancer Treatment

Keytruda, Merck's immunotherapy drug, generated nearly $30 billion in 2024 sales, marking a paradigm shift in cancer treatment since its 2014 launch, building upon research dating back to the late 19th century.

Keytruda's $30 Billion Success: Revolutionizing Cancer Treatment

Keytruda, Merck's immunotherapy drug, generated nearly $30 billion in 2024 sales, marking a paradigm shift in cancer treatment since its 2014 launch, building upon research dating back to the late 19th century.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the global significance of Keytruda's financial success and its impact on cancer treatment?

Keytruda, Merck Sharp and Dohme's cancer drug, generated over $130 billion in revenue since its 2014 launch, reaching nearly $30 billion in 2024 sales. This success is attributed to its pioneering role in immunotherapy, a revolutionary approach compared to traditional chemotherapy.

zeit.de

🌐 75% Global Worthiness

Apr 23, 10:10

German Pharma Booms Despite Stagnant Economy, US Tariffs Loom

The German pharmaceutical industry expects a 2.5% revenue increase and 1,100 new jobs in 2024, driven by increased US exports due to preemptive stockpiling ahead of potential US tariffs on medical products, while the overall German economy is projected to stagnate in 2025.

German Pharma Booms Despite Stagnant Economy, US Tariffs Loom

The German pharmaceutical industry expects a 2.5% revenue increase and 1,100 new jobs in 2024, driven by increased US exports due to preemptive stockpiling ahead of potential US tariffs on medical products, while the overall German economy is projected to stagnate in 2025.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of increased US demand for German pharmaceuticals on the German pharmaceutical industry?

The German pharmaceutical industry anticipates a 2.5% revenue increase and 2.9% production growth in 2024, with 1,100 new jobs, contrasting with the stagnant German economy. This growth is driven by increased exports, a stable domestic market, and preemptive stockpiling in the US due to threatened tariffs.", "This positive outlook is fueled by robust European and global demand for German pharmaceuticals and strategic stockpiling by US companies in anticipation of potential tariffs on medical products. US trade data and reports from freight carriers confirm increased pharmaceutical shipments to the US, mitigating potential tariff impacts.", "Despite the positive short-term outlook, potential US tariffs on medical products pose significant long-term challenges for the European pharmaceutical industry, potentially impacting profitability and access to vital inputs. The US remains a crucial export market for German pharmaceutical companies, representing almost 25% of total exports in 2024.

kathimerini.gr

🌐 85% Global Worthiness

Apr 16, 01:14

Pharma Companies Urge EU Action Against US Tariffs, Threatening Production Relocation

Nearly 30 multinational pharmaceutical companies urged EU intervention to counteract potential US tariffs on drugs, seeking compensation for innovation costs and regulatory simplification, citing the threat of production relocation to the US where prices are significantly higher.

Pharma Companies Urge EU Action Against US Tariffs, Threatening Production Relocation

Nearly 30 multinational pharmaceutical companies urged EU intervention to counteract potential US tariffs on drugs, seeking compensation for innovation costs and regulatory simplification, citing the threat of production relocation to the US where prices are significantly higher.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the long-term consequences of this situation on drug prices, innovation, and healthcare accessibility in Europe?

The pharmaceutical companies' request reflects concerns about the competitiveness of the EU market. The potential loss of production and the high costs associated with innovation and regulations could significantly impact the EU's pharmaceutical sector and patient access to medications. The EU's substantial pharmaceutical exports to the US (approximately €90 billion in 2023) are also at stake.

dailymail.co.uk

🌐 85% Global Worthiness

Apr 11, 01:16

Trump's Prescription Drug Tariffs: Potential for Higher Costs and Shortages

President Trump's plan to impose tariffs on prescription drugs, announced this week, aims to boost domestic production but risks increasing drug prices by an estimated $600 per household annually and worsening existing drug shortages, according to experts.

Trump's Prescription Drug Tariffs: Potential for Higher Costs and Shortages

President Trump's plan to impose tariffs on prescription drugs, announced this week, aims to boost domestic production but risks increasing drug prices by an estimated $600 per household annually and worsening existing drug shortages, according to experts.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How might the proposed tariffs impact the availability of essential medications, particularly those with limited suppliers?

The proposed tariffs are intended to address concerns about US dependence on foreign drug production, particularly from countries like China and India. While incentivizing domestic manufacturing, this policy risks exacerbating existing drug shortages and increasing healthcare costs, impacting both consumers and insurance companies.

Showing 73 to 84 of 152 results